Sunday 18 October 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
Insiders bought in the last twelve months.
22.75
2.43
−9.65%
Follow PBLS
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+1 more quarter Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (218.45) | |
P/B ratio |
— | — | — | 0.76 | |
Price to Tangible BV |
— | — | — | 0.76 | |
EV/Sales |
— | — | — | 0.00 | |
EV/EBITDA |
— | — | — | 1.87 | |
EV/Operating CF |
— | — | — | 2.73 | |
EV/FCF |
— | — | — | 2.71 | |
Quick Ratio |
— | 0.49 | 6.07 | 17.83 | |
Current Ratio |
— | 0.52 | 6.12 | 17.91 | |
Net Debt/EBITDA |
0.00 | 0.00 | 6.80 | 22.06 | |
Debt/Assets |
— | 18.00% | 2.79% | 0.58% | |
Debt/Equity |
— | (0.88) | 0.04 | 0.01 | |
Operating CF/Net income |
0.69 | — | 0.69 | 0.05 | |
Capex/Depreciation |
(0.02) | — | (0.61) | (1.60) | |
Interest Coverage |
(92.22) | — | (162.51) | (242.31) | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 26,606.08% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 7,876.35% | |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 2,455.41% | |
Graham Net Nets |
— | — | — | 1.26 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (221.63%) | |
Free Cash Flow Yield |
— | — | — | (15.06%) | |
Revenue per Share |
0.00 | — | 0.00 | 0.01 | |
Operating CF per Share |
(15.40) | — | (24.00) | (0.13) | |
Capex per Share |
(0.01) | — | (0.18) | (0.02) | |
Free Cash Flow per Share |
(15.41) | — | (24.18) | (0.15) | |
Cash per Share |
0.00 | 0.00 | 160.51 | 38.77 | |
Shareholders Equity per Share |
0.00 | 0.00 | 119.13 | 36.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 119.13 | 36.24 | |
Free Cash Flow |
(31.11) | — | (49.57) | (4.24) | |
Working Capital |
— | (27.43) | 277.83 | 1,062.56 | |
Capital Expenditures |
(0.02) | — | (0.37) | (0.62) | |
Net Current Asset Value |
— | (67.99) | 192.12 | 997.87 | |
EV/EBIT |
— | — | — | 1.84 | |
Capex to Sales |
0.00 | — | 0.00 | 4.16 | |
Price to Operating Income |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026